Videos

Antibody-drug conjugates like Rina-S may be able to salvage some of the responses that are often lost in the later lines of treatment, according to Elizabeth Lee, MD.

“There is, potentially, a role for Rina-S or other novel ADCs targeting different epitopes on the cancer cell surface,” Elizabeth Lee, MD, stated.

Experts discuss how to decide which robotic prostatectomy (RP) approach to utilize, considering factors such as patient characteristics, surgical outcomes, and the latest clinical evidence.

Experts discuss the role of PARP inhibitors in prostate cancer treatment, exploring their mechanisms, clinical benefits, and how they fit into current therapeutic strategies.

Experts discuss considerations for other androgen receptor inhibitors, highlighting their role in treatment strategies and how they impact patient outcomes in prostate cancer.

Experts give an overview of the treatment landscape in prostate cancer as of 2025.

Experts share clinical pearls on synthesizing risk assessment and response patterns in the management of advanced renal cell carcinoma.

Panelists discuss how the choice between chimeric antigen receptor T-cell (CAR T) therapy and autologous stem cell transplantation (auto-SCT) requires careful evaluation of multiple patient-specific factors. Medical professionals consider disease type and stage, prior treatments, patient age and fitness, cytogenetic risk, donor availability, and timing. CAR T may be preferred for relapsed/refractory cases, whereas transplant remains standard for eligible newly diagnosed patients.

Panelists discuss how patient-specific characteristics in diffuse large B-cell lymphoma significantly impact chimeric antigen receptor T-cell (CAR T) therapy outcomes, suggesting that standardized treatment algorithms may need refinement. Factors like tumor biology, immune status, and genetic profiles could help optimize therapeutic selection and sequencing.

Experts discuss risk score stability and post lenvatinib plus pembrolizumab treatment selection in renal cell carcinoma.

“As a field, we’re trying to push hard to make [radiation] patient-centered, and because of that, the field is the future of the field is pretty bright,” James B. Yu, MD, MHS, FASTRO, stated.

Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.

James B. Yu, MD, MHS, FASTRO, believes that 2 of the most intriguing and growing areas of radiation oncology are reirradiation of the prostate and bladder chemoradiation.

Most adverse effects observed in combination therapies for gastric cancers are associated with chemotherapy, according to Yelena Y. Janjigian, MD.

“The idea is that the patients are informed of the long-term consequences [of the treatments] so they can have some [input in] decision making,” Clara Bodelon, PhD, MS, stated.

Christina Henson, MD, spoke about the impact negative trial results can have on advancing the head and neck cancer field forward.

Experts discuss future directions and key insights in treating large B-cell lymphoma (LBCL).

Experts discuss the PD-L1 combined positive score (CPS) and its influence on treatment decisions as well as the clinical significance of a high CPS in guiding the use of immune checkpoint inhibitors such as pembrolizumab in HER2-positive gastric cancer.

Experts discuss safety management and monitoring protocols for liso-cel in treating relapsed/refractory large B-cell lymphoma.

Experts provide a safety summary of the phase 3 TRANSFORM study, highlighting key safety findings for liso-cel in relapsed/refractory large B-cell lymphoma.

Experts discuss Megan’s journey with HER2-positive upper gastrointestinal (GI) cancer, highlighting key treatment strategies and challenges.

Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.

Experts discuss how, nearly half of patients diagnoses with HER-2 positive metastatic brain cancer do develop brain metastasis. It is thought that larger molecule treatments such as the monoclonal antibodies likely do not cross an intact blood brain barrier which is often why patients develop brain metastases

“You have to come up with a novel twist in order to make an impactful study or get your own unique data set…” James B. Yu, MD, MHS, FASTRO, said in regard to creating interesting research.

Advances in perioperative targeted therapies may enable organ preservation and significantly enhance outcomes for patients with gastric cancers.

A lot of James B. Yu’s research begins with something as simple as a question from a patient regarding what aspects of treatment may be most beneficial.

Panelists discuss how next-generation sequencing is transforming precision oncology by enabling comprehensive genomic profiling that identifies actionable mutations, guides targeted therapy selection, and facilitates clinical trial enrollment while acknowledging challenges in data interpretation and implementation across diverse health care settings.

Panelists discuss how sequencing different therapies and personalizing care for their patients requires careful consideration of disease characteristics, prior treatment response, comorbidities, toxicity profiles, and patient preferences to optimize outcomes and quality of life.

Panelists discuss how recent clinical trials have shaped treatment algorithms for metastatic renal cell carcinoma (mRCC) by establishing the superiority of immunotherapy–tyrosine kinase inhibitor combinations over single-agent therapies across various risk groups.